Live Attenuated Influenza Vaccine (FluMist®)

(This information is current for the 2024-25 influenza season)

Vaccine Description	Brand: FluMist Trivalent® Live virus, nasally administered influenza vaccine, contains egg protein, gelatin, and gentamicin. See package insert. It is important to review CDC/ACIP guidelines for LAIV use before each flu season.		
Dose & Route	 Dose: 0.2 mL (administered as 0.1 mL per nostril) See package insert for administration guidance. 		
Indications	 Healthy non-pregnant persons 2 through 49 years of age NOT indicated for immunization of people younger than 2 years or older than 49 years, nor for treatment of influenza, nor will it protect against infection and illness caused by infectious agents other than the included influenza A or B viruses 		
	Age Groups	Vaccination Status	Dosage/Schedule
Administration Schedule	Children ages 2 years through 8 years	Not previously vaccinated against influenza or did not receive 2 or more doses since July 1, 2010	Two doses (separated by ≥ 4 weeks) are recommended for children 2 - 8 years of age if they have not received 2 doses in prior seasons (does not need to be same or consecutive seasons). Both doses should be administered even if the child turns 9 years of age between receipt of dose 1 and dose 2.
	Children and adults ages 9 through 49 years	Not applicable	1 dose (0.2 mL) <u>per</u> season
Contraindications	 Do not give influenza vaccine to a child or adolescent (2 to 17 years of age) who has: Experienced an anaphylactic reaction to a prior dose of the vaccine or to any of its components. For a list of vaccine components, go to the CDC Pink Book Appendix B or refer to the manufacturer's package insert at https://health.mil/flu. Chronic aspirin or salicylate-containing medication therapy because of the risk for Reye syndrome No spleen or a non-functioning spleen Known or suspected immune-deficiency diseases, such as combined immunodeficiency, agamma-globulinemia, and thymic abnormalities, or leukemia, lymphoma or malignancy (continues on next page) 		

Live Attenuated Influenza Vaccine

(Continued)

Contraindications (continued)	 Immune suppression or immune compromised due to treatment with systemic corticosteroids, alkylating drugs, antimetabolites, radiation, or other immune suppressing therapies Pregnancy Received influenza antivirals (e.g., oseltamivir and zanamivir within the previous 48 hours; peramivir within the previous 5 days; or baloxavir within the previous 17 days) Children aged 2-4 years diagnosed with asthma or whose caregivers report a wheezing episode w/i the past 12 months Persons with leak between the CSF and the oropharynx, nasopharynx, nose, or ear or any other cranial CSF leak Persons with cochlear implants 	
Precautions	 Moderate or severe acute illness (including nasal congestion) History of Guillain-Barré Syndrome within 6 weeks of a previous influenza vaccine receipt Chronic conditions that place children at high risk for complications from influenza illness (e.g., heart disease, diabetes, renal disease, sickle cell anemia) Asthma in people 5 years and older 	
Special Considerations	 Give inactivated influenza vaccine (IIV) instead of LAIV to individuals who are in close contact with others who are severely immune-compromised LAIV may be given at the same time as other live injectable vaccines, including MMR or varicella. But if two live vaccines are not given on the same day, they should be given at least 4 weeks apart. Defer administration if nasal congestion might prevent LAIV from reaching nasopharyngeal mucosa See Storage and Handling section 	
Patient screening: www.health.i	mil/fluscreening	

- Patient screening: www.health.mil/fluscreening
- VIS: http://www.cdc.gov/vaccines/hcp/vis/vis-statements/flulive.html
- Standing orders: <u>www.health.mil/standingorders</u>
- Additional education may be found at www.health.mil/flu